| Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells M Norelli, B Camisa, G Barbiera, L Falcone, A Purevdorj, M Genua, ... Nature medicine 24 (6), 739-748, 2018 | 1300 | 2018 |
| CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma M Casucci, B Nicolis di Robilant, L Falcone, B Camisa, M Norelli, ... Blood, The Journal of the American Society of Hematology 122 (20), 3461-3472, 2013 | 401 | 2013 |
| Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional CAR-T cells co-expressing a suicide gene M Casucci, L Falcone, B Camisa, M Norelli, S Porcellini, A Stornaiuolo, ... Frontiers in immunology 9, 507, 2018 | 93 | 2018 |
| Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens G Escobar, L Barbarossa, G Barbiera, M Norelli, M Genua, A Ranghetti, ... Nature Communications 9 (1), 2896, 2018 | 57 | 2018 |
| Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effects M Norelli, M Casucci, C Bonini, A Bondanza Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1865 (1), 90-100, 2016 | 47 | 2016 |
| Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis R Biavasco, E Lettera, K Giannetti, D Gilioli, S Beretta, A Conti, S Scala, ... Nature Communications 12 (1), 4559, 2021 | 26 | 2021 |
| Modeling human graft-versus-host disease in immunocompromised mice M Norelli, B Camisa, A Bondanza Tumor Immunology: Methods and Protocols, 127-132, 2016 | 5 | 2016 |
| myeloid leukemia and multiple myeloma CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma M Casucci, B Nicolis, L Falcone, B Camisa, M Norelli, P Genovese Blood 122, 3461-3472, 2013 | 4 | 2013 |
| Monocyte-Derived IL-1 and IL-6 are Differentially Required for Cytokine Release Syndrome and Neurotoxicity by CAR-T Cells M Norelli, B Camisa, G Barbiera, L Falcone, A Purevdorj, M Genua, ... MOLECULAR THERAPY 26 (5), 10-11, 2018 | 2 | 2018 |
| Off-tumor target expression levels do not predict CAR-T cell killing: a foundation for the safety of CD44v6-targeted T cells M Casucci, BN di Robilant, L Falcone, B Camisa, M Norelli, B Gentner, ... Blood 122 (21), 142, 2013 | 2 | 2013 |
| Monocytes are required for both optimal anti-leukemic efficacy and the cytokine release syndrome by CAR-T cells: lessons from an innovative xenotolerant mouse model M Norelli, M Casucci, B Camisa, L Falcone, C Traversari, C Bordignon, ... Blood 128 (22), 997, 2016 | 1 | 2016 |
| Il-1 antagonist and toxicity induced by cell therapy A Bondanza, B Camisa, M Norelli US Patent App. 16/978,897, 2021 | | 2021 |
| Il-1 antagonist and toxicity induced by cell therapy A Bondanza, B CAMISA, M NORELLI | | 2021 |
| Oncogene-induced senescence in haematopoietic progenitors features myeloid-restricted hematopoiesis and histiocytosis R Biavasco, E Lettera, M Norelli, B Camisa, D Cesana, P Gallina, ... HUMAN GENE THERAPY 29 (12), A37-A37, 2018 | | 2018 |
| Oncogene-Induced Senescence in Hematopoietic Progenitors Leads to Myeloid-Restricted Hematopoiesis, Chronic Inflammation and Histiocytosis R Biavasco, E Lettera, M Norelli, B Camisa, D Cesana, P Gallina, ... MOLECULAR THERAPY 26 (5), 372-372, 2018 | | 2018 |
| BRAFV600E expression in haematopoietic progenitors leads to senescence, myeloid skewing and aggressive histiocytosis R Biavasco, E Lettera, M Norelli, B Camisa, D Cesana, P Gallina, ... HUMAN GENE THERAPY 28 (12), A19-A19, 2017 | | 2017 |
| MONOCYTES ARE REQUIRED FOR BOTH OPTIMAL ANTI-LEUKEMIC EFFICACY AND RELATED TOXICITIES BY CAR-T CELLS M Norelli, M Casucci, B Camisa, L Falcone, C Traversari, C Bordignon, ... HAEMATOLOGICA 102, 7-7, 2017 | | 2017 |
| OP0179 Brafv600e promotes myeloid skewing in multisystemic langerhans cell histiocytosis humanized mouse model R Biavasco, M Norelli, B Camisa, D Cesana, P Gallina, B Gentner, ... Annals of the Rheumatic Diseases 76 (Suppl 2), 126-126, 2017 | | 2017 |
| Modeling the cytokine release syndrome and its treatment in a long-term xenotolerant mouse model of CAR-T cell immunotherapy M Norelli, M Casucci, B Camisa, L Falcone, A Saudemont, F Ciceri, ... HUMAN GENE THERAPY 27 (11), A31-A31, 2016 | | 2016 |
| 512. The Cytokine Release Syndrome Crucially Contributes to the Anti-Leukemic Effects of CD44v6 CAR-T Cells M Norelli, M Casucci, B Camisa, L Falcone, A Saudemont, L Naldini, ... Molecular Therapy 24, S204, 2016 | | 2016 |
